Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other rare disease areas with significant unmet medical needs. Zealand employs more than 300 people in Denmark and the US and has a portfolio of medicines and product candidates, including license collaborations with Boehringer Ingelheim.
Our pipeline focusing on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and commercialization, while opportunistically considering partnership relationships that may arise.
1998
HeadquartersSydmarken 11, 2860 Søborg – Denmark
51,513,186
IPOJan. 1, 2000
Stock exchange(s)Nasdaq Copenhagen